IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:) Art Unit: 1636
WESTAWAY, et al.) Our Ref. 45930.3.0
Serial :	No.: 09/580,476) Examiner: David Guzo
Filed:	26 May 2000	I hereby certify that this correspondence is being:
For:	FLAVIVIRUS EXPRESSION AND DELIVERY SYSTEM) [X] deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 [] facsimile transmitted to the Patent and Trademark Office [] hand delivered to the Patent and Trademark Office on this 3 day of February, 2004 By Mally Howy
To:	Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	

SUBMISSION OF SEQUENCE ID LISTING

This submission is filed in response to the Office Action mailed 03 December 2003, the period for response to which has been extended to 03 February 2004 by the accompanying Petition for Extension of Time. A Sequence ID Listing had been previously submitted in this case. The present Action identifies additional nucleotide sequences at Figure 2 of the instant specification, and requests that they be provided in the form of a sequence ID listing as well.

Enclosed herewith is an amended nucleotide sequence ID listing for the above stated patent application, including the sequences previously provided, together with those in Figure 2. Please find both the paper copy and the computer readable copy submitted in accordance with 37 CFR 1.821(c) and 37 CFR 1.821(e) respectively. Also enclosed is a further Amendment to the specification, in order to provide replacement Figure 2 in accordance with the requirements of 37 CFR 1.821(d).

In submitting this disclosure I hereby state that the information recorded in computer readable form is identical to the written sequence on the paper copy, and includes no new matter.

Dated: 3 FEB 20

Respectfully submitt

Philip M. Goldman Registration No. 31,162 Fredrikson & Byron, P.A. 4000 Pillsbury Center

200 South Sixth Street



Application No.

09/580,476

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING MUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

AUGIEOTIDE REQUENCE AND/OR ANIMO NOID BEZONMON DESCRIPTION
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
1772
1. This application clearly fails to comply with the requirements of 37 CFR 1.821
- 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on
caper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been
submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted.
However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been
found to be damaged and/or unreadable as indicated on the attached CRP Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR
1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer
readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7.
other: - Sequences in Fig 2 are not in Sequence Listing
₹
Applicant must provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence
Listing"
An initial or substitute paper copy of the "Sequence Listing", as well as an
amendment directing its entry into the specification
A statement that the content of the paper and computer readable copies are the same
and, where applicable, include no new matter, as required by 37 CFR 1.821(e) ϕ r 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
For questions regarding compliance with these requirements, please contact:
For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212 For Patentin software help, call (703) 557-0400